Chevallard Daniel R.
CIK 0001706176 Name as filed on the most recent filing
Filed as Chevallard Daniel R. (17)
19 transaction lines · from 17 filings · filed 2017-07-25 to 2026-03-30 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
- ISSUER Lenz Therapeutics, Inc. 3 filings
- ISSUER Viracta Therapeutics, Inc. 10 filings
- ISSUER Regulus Therapeutics Inc. 4 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
19 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2026-03-27 |
Lenz Therapeutics, Inc. LENZ |
P, Open-market purchase | 7,500 acquired | 8.57 | 64,275.00 | Form 4, filing 0001706176-26-000004 | |
| 2025-11-07 |
Lenz Therapeutics, Inc. LENZ |
P, Open-market purchase | 2,178 acquired | 22.76 | 49,562.79 | Form 4, filing 0001815776-25-000072 | |
| 2025-11-07 |
Lenz Therapeutics, Inc. LENZ |
P, Open-market purchase | 20 acquired | 22.71 | 454.20 | Form 4, filing 0001815776-25-000072 | |
| 2024-05-14 |
Lenz Therapeutics, Inc. LENZ |
P, Open-market purchase | 3,188 acquired | 15.68 | 49,987.84 | Form 4, filing 0001815776-24-000046 | |
| 2024-02-27 |
Viracta Therapeutics, Inc. VIRX |
S, Open-market sale | 3,405 disposed | 0.73 | 2,493.14 | Form 4, filing 0001209191-24-004037 | |
| 2023-11-28 |
Viracta Therapeutics, Inc. VIRX |
S, Open-market sale | 3,720 disposed | 0.50 | 1,860.00 | Form 4, filing 0001209191-23-056842 | |
| 2023-08-28 |
Viracta Therapeutics, Inc. VIRX |
S, Open-market sale | 3,512 disposed | 1.45 | 5,092.40 | Form 4, filing 0001209191-23-047665 | |
| 2023-05-25 |
Viracta Therapeutics, Inc. VIRX |
S, Open-market sale | 3,635 disposed | 1.42 | 5,160.25 | Form 4, filing 0001209191-23-032707 | |
| 2023-02-27 |
Viracta Therapeutics, Inc. VIRX |
S, Open-market sale | 3,599 disposed | 1.68 | 6,050.64 | Form 4, filing 0001209191-23-013854 | |
| 2022-11-28 |
Viracta Therapeutics, Inc. VIRX |
S, Open-market sale | 3,532 disposed | 2.72 | 9,605.63 | Form 4, filing 0001209191-22-058981 | |
| 2022-08-26 |
Viracta Therapeutics, Inc. VIRX |
S, Open-market sale | 3,655 disposed | 4.02 | 14,679.21 | Form 4, filing 0001209191-22-047948 | |
| 2022-05-26 |
Viracta Therapeutics, Inc. VIRX |
S, Open-market sale | 3,596 disposed | 1.90 | 6,836.36 | Form 4, filing 0001209191-22-032665 | |
| 2022-02-28 |
Viracta Therapeutics, Inc. VIRX |
S, Open-market sale | 3,998 disposed | 2.78 | 11,112.44 | Form 4, filing 0001209191-22-014438 | |
| 2021-11-29 |
Viracta Therapeutics, Inc. VIRX |
S, Open-market sale | 4,325 disposed | 4.82 | 20,842.61 | Form 4, filing 0001209191-21-067045 | |
| 2021-11-26 |
Viracta Therapeutics, Inc. VIRX |
S, Open-market sale | 3,254 disposed | 4.80 | 15,621.15 | Form 4, filing 0001209191-21-067045 | |
| 2019-07-01 |
Regulus Therapeutics Inc. RGLS |
S, Open-market sale | 2,669 disposed | 1.31 | 3,500.39 | Form 4, filing 0001209191-19-040500 | |
| 2019-05-15 |
Regulus Therapeutics Inc. RGLS |
S, Open-market sale | 10,000 disposed | 1.41 | 14,089.00 | Form 4, filing 0001209191-19-030506 | |
| 2019-04-01 |
Regulus Therapeutics Inc. RGLS |
S, Open-market sale | 3,253 disposed | 0.98 | 3,192.49 | Form 4, filing 0001209191-19-023087 | |
| 2017-07-25 |
Regulus Therapeutics Inc. RGLS |
P, Open-market purchase | 54,945 acquired | 0.91 | 49,999.95 | Form 4, filing 0001209191-17-046232 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- P, Open-market purchase
- Open-market purchase
- S, Open-market sale
- Open-market sale
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.
- Open-market purchase 5
- Open-market sale 14
- Option exercise 0
- Grant or award 0
- Tax withholding 0
- Disposition to the issuer 0
- In-the-money option exercise 0
How to cite this page
ebomi catalog. Chevallard Daniel R., insider transactions. Retrieved 2026-08-20 from https://ebomi.com/insider/0001706176
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6